Search results for " metastasis"

showing 10 items of 623 documents

Stage IV breast cancer: a population-based study about prognostic factors according to HER2 and HR status

2015

International audience; We aim to describe trends in net survival (NS) and to assess the prognostic factors among women with de novo metastatic breast cancer (MBC) according to human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) status. Data on women suffering from de novo MBC and diagnosed from 1998 to 2009 were provided by the Côte-d'Or breast cancer registry. NS was described using the Pohar Perme estimator and prognostic factors were investigated in a generalised linear model. We identified 232 patients (mean age = 64.7). Median NS was 29.2 months, 1- and 5-year NS were 76% and 26% respectively. The survival trend in patients with HER2-positive tumours who did not …

Oncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsLower riskBreast cancerTrastuzumabInternal medicinemedicineHumansNeoplasm Metastasisskin and connective tissue diseasesAgedNeoplasm StagingGynecologyregisterbusiness.industryCarcinoma Ductal BreastAge FactorsAbsolute risk reductionhormone receptorsCancerTriple Negative Breast NeoplasmsMiddle AgedTrastuzumabHER2 receptorsPrognosismedicine.diseaseMetastatic breast cancerConfidence interval3. Good healthpopulation-basedCarcinoma LobularReceptors EstrogenOncologyLinear ModelsFemalemetastatic breast cancernet survivalReceptors Progesteronebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

The treatment of advanced gastric cancer: current strategies and future perspectives.

2008

Oncologymedicine.medical_specialtybusiness.industryAdvanced stageCancerHematologyAdvanced gastric cancermedicine.diseasePrognosisGastroenterologyOncologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisbusinessStomach cancerForecastingAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer

1983

At the end of 1976 and the beginning of 1977 respectively, the EORTC Genito-Urinary Tract Cancer Cooperative Group started two randomized phase III protocols in previously untreated patients with advanced T3–4 prostatic cancer (1–3). The first trial, 30762, compared Stilboestrol and Estracyt, while the second, 30761, was a randomized comparison of Stilboestrol, Cyproterone Acetate and Medroxyprogesterone Acetate. Both trials have now been closed to patient entry and the principal endpoints of the studies analyzed. This paper will present the interim results which have emerged from these two studies.

Oncologymedicine.medical_specialtybusiness.industryBone metastasisCyproterone acetateCancermedicine.diseaselaw.inventionCardiovascular deathchemistry.chemical_compoundchemistryRandomized controlled triallawInternal medicinemedicineMedroxyprogesterone acetateCooperative groupbusinessmedicine.drug
researchProduct

Current challenges in metastasis: Disseminated and circulating tumor cells detection

2014

Metastatic dissemination of the primary tumor is responsible for the majority of cancer-related morbidity and mortality. Detection of disseminated tumor cells in the bone marrow and circulating tumor cells in the peripheral blood is associated with early metastatic recurrence in cancer. Circulating tumor cells (CTCs) shed from the site of disease in metastatic or primary tumor that can be recognized and enriched in the peripheral blood of cancer patients. The detection of rare circulating tumor cells (CTC) is an objective of numerous oncologists' researches. Circulating tumor cells have the potential to help to detect cancer recurrence at its earlier stage, determine therapy resistance befo…

Oncologymedicine.medical_specialtybusiness.industryImmunologyCancerGeneral MedicineDiseaseNeoplastic Cells Circulatingmedicine.diseasePrimary tumorMetastasisClinical trialmedicine.anatomical_structureCirculating tumor cellNeoplasmsInternal medicinemedicineHumansImmunology and AllergyBone marrowNeoplasm MetastasisNeoplasm Recurrence LocalStage (cooking)businessHuman Antibodies
researchProduct

Preoperative Radiochemotherapy and Radical Surgery of Advanced Head and Neck Cancers — Results of a Prospective, Multicenter DÖSAK Study

1994

Present research concerning the efficiacy of therapeutic strategies for squamous cell carcinomas of the oral cavity and the oropharynx profits from former observational studies. The so-called retrospective German, Austrian, and Swiss Association for Head and Neck Tumors (DOSAK) study (Platz et al. 1986) served to review existing proposals for classification (UICC 1973, 1978; AJC 1978) and to develop a statistical classification which enables the head and neck oncologist to define prognostically homogeneous patient collectives. The treatment-dependent prognostic index (TPI) was the corresponding result (Platz et al. 1982).

Oncologymedicine.medical_specialtybusiness.industryMultimodality TreatmentHead and neck tumorsOral cavityHomogeneousInternal medicinemedicineObservational studyRadical surgeryTumor node metastasisbusinessHead and neck
researchProduct

37 Quantitative evaluation of lymph-vascular space invasion (LVSI) in patients affected by endometrial cancer: prognostic and clinical implications

2020

Objectives Lymph-vascular space invasion (LVSI) is associated with an increased risk of recurrence. Usually, the interpretation of LVSI is just qualitative, as presence or absence. The aim of this study is to examine the quantitative analysis of LVSI. Methods Retrospective multicentre study. It included 2300 consecutive patients who received a histologically confirmed diagnosis of endometrial cancer between January 2000 and December 2018 at the Gynaecologic Oncology Unit of two tertiary hospitals in Italy. Results The rate of lymph node metastasis increased from the 5% in patients with no LVSI, to 15% in patients with focal LVSI and 33% in those with diffuse LVSI (p Conclusion The presence …

Oncologymedicine.medical_specialtybusiness.industryNodal metastasisEndometrial cancerLymph node metastasismedicine.diseaseVascular spaceIncreased riskInternal medicinemedicineIn patientLymphbusinessGrading (tumors)Oral Poster – TAPED
researchProduct

HIFU for Bone Metastases and other Musculoskeletal Applications

2018

AbstractHigh-intensity focused ultrasound (HIFU) is a totally noninvasive procedure that has shown promising results in the management of numerous malignant and nonmalignant conditions. Under magnetic resonance or ultrasound guidance, high-intensity ultrasound waves are focused on a small, well-defined target region, inducing biologic tissue heating and coagulative necrosis, thus resulting in a precise and localized ablation. This treatment has shown both great safety and efficacy profiles, and may offer a multimodal approach to different diseases, providing pain palliation, potential local tumor control, and, in some cases, remineralization of trabecular bone. In musculoskeletal field, HIF…

Osteoid osteomamedicine.medical_specialtymedicine.medical_treatment030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineinterventional radiologymedicineRadiology Nuclear Medicine and imagingbone metastasemedicine.diagnostic_testbusiness.industryVascular malformationUltrasoundBone metastasisMagnetic resonance imagingInterventional radiologymedicine.diseaseosteoid osteomaHigh-intensity focused ultrasoundCoagulative necrosisHigh-intensity focused ultrasoundpain palliation030220 oncology & carcinogenesisRadiologyCardiology and Cardiovascular Medicinebusiness
researchProduct

Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovaria…

1994

The effects of E-64 (Cathepsin B and L inhibitor) and Pepstatin A (Cathepsin D inhibitor) on spontaneous and experimental metastasis formation were investigated in mice with MCa mammary carcinoma, M5076 ovarian sarcoma and L1210 leukemia. Pepstatin induced a marked decrease in the number of spontaneous metastasis in MCa or M5076 tumor bearing mice. This phenomenon was also noted with E-64 but only in M5076 tumor bearing mice. On the other hand, both these agents were unable to prevent the formation of experimental metastasis in mice injected i.v. with L1210, MCa or M5076 tumor cells or with tumor cells in which Cathepsin B, L and D activities were inhibited by a 24 hour continuous exposure …

Ovarian NeoplasmsCathepsin LMammary Neoplasms ExperimentalpepstatinCysteine Proteinase Inhibitorsproteinase inhibitors.Cathepsin DCathepsinsCathepsinCathepsin BCysteine EndopeptidasesMiceLeucineEndopeptidasesPepstatinsTumor Cells CulturedAnimalsmetastasiFemaleNeoplasm MetastasisLeukemia L1210E-64In vivo (Athens, Greece)
researchProduct

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model

2012

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34+ cells (CD34-TRAIL+), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2+ and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL+ cel…

PathologyCancer ResearchCD34Antigens CD34ApoptosisMice SCIDMetastasisMetastasisTNF-Related Apoptosis-Inducing LigandMicePreclinical StudyMice Inbred NODNeoplasm Metastasisskin and connective tissue diseasesHeterologousTumorbiologyCell DeathCancer stem cellsTumor BurdenOncologyNeoplastic Stem CellsTumor necrosis factor alphaFemalemedicine.medical_specialtyTRAIL BREAST CANCERTransplantation HeterologousBreast NeoplasmsSCIDCell LineTriple-negative breast cancerCancer stem cellCell Line TumormedicineAnimalsHumansAntigensTransplantationCD44Mesenchymal stem cellmedicine.diseaseApoptosisCell culturebiology.proteinCancer researchInbred NODCD34Settore MED/36 - Diagnostica Per Immagini E RadioterapiaAnimals; Antigens CD34; Apoptosis; Breast Neoplasms; Cell Death; Cell Line Tumor; Female; Humans; Mice; Mice Inbred NOD; Mice SCID; Neoplasm Metastasis; Neoplastic Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Transplantation Heterologous; Tumor BurdenmTRAIL
researchProduct

Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients

2014

The importance of inflammation is increasingly noticed in cancer. The aim of this study was to analyze the prognostic influence of pre-operative serum C-reactive protein (CRP) in a cohort of 148 lymph node-negative breast cancer patients. The prognostic significance of CRP level for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) was evaluated using univariate and multivariate Cox regression, also including information on age at diagnosis, tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, proliferation index (Ki67) and molecular subtype, as well as an assessment of the…

PathologyProliferation indexReceptor ErbB-2lcsh:MedicineEstrogen receptorGastroenterologyMetastasisCohort StudiesBasic Cancer ResearchBreast TumorsMedicine and Health SciencesMedicineNeoplasm Metastasislcsh:ScienceImmune ResponseAged 80 and overUnivariate analysisMultidisciplinarybiologyCancer Risk FactorsHazard ratioObstetrics and GynecologyMiddle AgedPrognosisGene Expression Regulation NeoplasticC-Reactive ProteinOncologyReceptors EstrogenFemaleReceptors ProgesteroneResearch ArticleCancer Predisposing Conditions and SyndromesAdultmedicine.medical_specialtyImmunologyBreast NeoplasmsDisease-Free SurvivalBreast cancerInternal medicineBreast CancerHumansImmune EvasionAgedCell ProliferationProportional Hazards ModelsInflammationGenome Humanbusiness.industryProportional hazards modelGene Expression Profilinglcsh:RC-reactive proteinImmunityBiology and Life SciencesCancers and NeoplasmsCancermedicine.diseaseKi-67 Antigenbiology.proteinWomen's Healthlcsh:QClinical ImmunologyLymph NodesbusinessPLoS ONE
researchProduct